Computer program to help identify brain tumor types on MRI scans
Tests an artificial intelligence tool reading MRI scans of adults with malignant brain tumors.
Key facts
- Who runs it
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Where
- China2 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- AI-assisted Diagnosis of Malignant Brain Tumors
- Status
- Recruiting
- People taking part
- 3,000 people, planned
- Started
- 1 Sept 2025
- Expected to end
- 31 Dec 2028
- Type of study
- Observational
- Record updated
- 30 September 2025
Who can take part
The trial is looking for adults with glioma, brain metastases or brain lymphoma confirmed by tissue testing, who had a full MRI scan before surgery. Their past scans will be used to build an AI tool that helps tell brain tumour types apart.
- Age
- 18 Years to 100 Years
- Sex
- All
- Disease stage
- Glioma, brain metastases (cancer that spread to the brain) or brain lymphoma, confirmed by tissue testing (pathology).
- Earlier treatment
- People who had brain surgery or radiotherapy before cannot join. A complete MRI before surgery is needed.
- Main reasons for not taking part
- Poor quality MRI images
- Earlier brain surgery
- Earlier radiotherapy
- Other lesions inside the skull
Show the full registry criteria (2)Hide the full registry criteria
Who can take part
- Patients diagnosed with glioma, brain metastases, and brain lymphoma by pathology, with the patient being at least 18 years old; preoperative MRI was complete
Who cannot take part
- Poor image quality; history of previous brain surgery or radiotherapy; accompanied by other intracranial lesions
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Gliomas or lymphoma
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study aims to establish a large-scale, multi-center MRI database for malignant brain tumors. It will develop an artificial intelligence system for the segmentation and classification of multiple subtypes of brain tumors (including glioma, metastatic tumor and lymphoma et al.) using deep learning technology. This will address the issues of small sample sizes and limited classification performance in existing methods, thereby improving the accuracy of non-invasive preoperative diagnosis, reducing the need for biopsies, and having significant clinical translational value.
The group in the trial
- malignant brain tumors
Retrospectively collected cases of malignant brain tumors (including gliomas, brain metastases, and brain lymphomas) that were confirmed by histopathology and had preoperative multimodal MRI images (mainly including CE-T1WI and T2-FLAIR) over the past 10 years
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Research on AI-assisted Diagnosis of Common Malignant Brain Tumors Based on Magnetic Resonance Imaging
- Plain-language title
- Computer program to help identify brain tumor types on MRI scansGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT07198256, who can take part
- Record updated
- 30 September 2025